Phase I/II clinical trial of HLA-A24 restricted epitope peptide cocktail therapy with UFT+LV for patients with advanced metastatic colorectal cancer.
收藏NIAID Data Ecosystem2026-03-07 收录
官方服务：
资源简介：
Interventions: Subcutaneous injection of cancer vaccine (seven peptides) UFT+LV Primary outcome(s): Safty Immunological response (in vitro CTL induction) Study Design: Single arm Non-randomized
创建时间：
2011-09-15
